GALAD Demonstrates High Sensitivity for HCC Surveillance in a Cohort of Patients with Cirrhosis.

Amit G SingalTayob NabihahAnand MehtaJorge A MarreroHashem El-SeragQingchun JinCristian Saenz de ViteriAustin FobarNeehar D Parikh

Published in: Hepatology (Baltimore, Md.) (2021)

GALAD demonstrated high sensitivity for HCC detection in a cohort of patients with cirrhosis. Validation of these results are warranted in large phase III datasets.

Keyphrases

phase iii
open label
clinical trial
public health
double blind
phase ii
placebo controlled
randomized controlled trial